New Sustained Release Drug Enters Trials

Aerie Pharmaceuticals, Inc. (Aerie), has begun patient dosing in their first human clinical trial of a sustained release implant in patients with wet macular degeneration or diabetic macular edema. The polymer implant provides controlled release of AR-13503, an injectable drug that inhibits blood vessel growth in the retina, while potentially reducing the treatment burden associated [Read More]

Updating The Home For Better Living With Wet AMD

Leading patient advocacy organizations collaborate on important new resource Living with wet age-related macular degeneration (AMD) poses some difficult challenges, but a new free resource called “My Home in Sight Kit” can help make adapting the living space easier. Prevent Blindness has joined with five other patient advocacy organizations* to share valuable advice based upon five [Read More]